EYPT analyst estimates
EyePoint (EYPT) analyst ratings, the average price target and its range, and every firm's latest call.
- 10 firms rate EYPT: 3 buy, 6 hold, 1 sell.
- The average price target is $11.21 from None analysts, from $0.50 to $40.00.
EYPT analyst ratings and price targets
| Date | Firm | Call | Target |
|---|---|---|---|
| Oct 20, 2026 | Mizuho Securities | Mizuho Downgrades EyePoint Inc. (EYPT) to Neutral 'on Negative P3 Data, Lack of Catalysts, Financing Overhang' | $0.50 |
| Oct 20, 2026 | RBC Capital | EyePoint Inc. (EYPT) PT Lowered to $1 at RBC Capital | $1.00 |
| Oct 19, 2026 | Jefferies | EyePoint downgraded to Hold from Buy at Jefferies | $1.00 |
| Sep 2, 2026 | China Renaissance Securities (US) Inc. | TD Cowen Downgrades EyePoint Inc. (EYPT) to Hold | $4.00 |
| Aug 18, 2026 | RBC Capital | EyePoint downgraded to Sector Perform from Outperform at RBC Capital | $5.00 |
| Aug 18, 2026 | Chardan Capital | EyePoint downgraded to Neutral from Buy at Chardan | $5.00 |
| Aug 17, 2026 | Jefferies | EyePoint price target lowered to $8 from $30 at Jefferies | $8.00 |
| Aug 6, 2026 | H.C. Wainwright | EyePoint price target lowered to $27 from $30 at H.C. Wainwright | $27.00 |
| Jul 29, 2026 | Mizuho Securities | EyePoint Inc. (EYPT) PT Raised to $39 at Mizuho, 'Top Pick' | $39.00 |
| Jul 15, 2026 | Stifel Nicolaus | EyePoint initiated with a Buy at Stifel | $40.00 |
| Feb 19, 2026 | Mizuho Securities | EyePoint price target raised to $36 from $33 at Mizuho | $36.00 |
| Feb 5, 2026 | RBC Capital | RBC Capital on EyePoint Inc. (EYPT): 'We See Recent Weakness as Buying Opportunity' | $39.00 |
| Oct 29, 2025 | Mizuho Securities | EyePoint price target raised to $33 from $28 at Mizuho | $33.00 |
| Oct 20, 2025 | Mizuho Securities | Mizuho Reiterates Outperform Rating on EyePoint Pharmaceuticals, Inc. (EYPT) | $28.00 |
| Nov 11, 2024 | H.C. Wainwright | EyePoint Pharmaceuticals, Inc. (EYPT) PT Lowered to $22 at H.C. Wainwright | $22.00 |